Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]

Suleiman Massarweh, Edward Romond, Esther P. Black, Emily Van Meter, Brent Shelton, Vera Kadamyan-Melkumian, Mark Stevens, Richard Elledge

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Fingerprint

Dive into the research topics of 'Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9]'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science